C16 Ceramide; N-palmitoyl-sphingosine; C16 Cer; N-(hexadecanoyl)-sphing-4-enine; N-palmitoyl-D-erythro-sphingosine; N-acylsphingosine; Cer(d18:1/16:0); N-(palmitoyl)-ceramide; N-hexadecanoylsphingosine; N-(hexadecanoyl)-ceramide; CHEMBL35292; Ceramide (d18:1/16:0); N-((E,2s,3r)-1,3-Dihydroxyoctadec-4-En-2-Yl)palmitamide; C16-d-Erythro-sphingosine; C16-0(Palmitoyl)ceramide; D-erythro-Sphingosine, N-Palmitoyl-; Ceramide d34:1; N-(palmitoyl)ceramide; N-(hexadecanoyl)ceramide; N-palmitoylsphing-4-enine; N-hexadecanoylsphing-4-enine; sphing-4-enine-16-ceramide; BSPBio_001281; BML3-D03; N-(hexadecanoyl)sphing-4-enine; SCHEMBL10298591; SCHEMBL16027983; HMS1361A03; HMS1791A03; HMS1989A03; HMS3402A03; N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide; ZINC8860497; BDBM50289523; LMSP02010004; IDI1_033751; NCGC00161362-01; NCGC00161362-02; NCGC00161362-03; N-Palmitoyl-D-sphingosine, >=98.0% (TLC); C16 Ceramide (N-Palmitoylsphingosine, D-erythro); J-015630; (2S,3R)-2-(Hexadecanoylamino)-4-octadecene-1,3-diol; N-[(2S,3R,4E)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide; C16 Ceramide (d18:1/16:0), N-palmitoyl-D-erythro-sphingosine, powder; Hexadecanoic acid ((E)-(1S,2R)-2-hydroxy-1-hydroxymethyl-heptadec-3-enyl)-amide; N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]hexadecanamide